Forget Chasing 7% Yields: These 5 Dividend Stocks Offer Something Different

Treasury yields still compete with dividend stocks for income money. So payouts backed by real free cash flow matter more than the headline yield. The five mega-caps below yield between roughly 2.2% and 2.9%, cover their dividends with room to spare, and have raised them through multiple cycles. One of them has grown its annual dividend per share for 43 consecutive years. The common thread is simple. These companies share growing cash generation, payout ratios near or below two-thirds of earnings, and boards with long records of raising the payout.

AbbVie: Immunology Growth Funds a Raise Every Year Since 2013

AbbVie (NYSE:ABBV | ABBV Price Prediction) yields 2.32% on a quarterly dividend of $1.73 per share, or $6.92 annualized. The next check comes November 16, 2026.

Dividend safety: Measured against the low end of AbbVie’s full-year 2026 adjusted EPS guidance of $13.87 to $14.07, the annual dividend takes about 50% of earnings. The free cash flow yield is 3.54%, well above the dividend yield. The payout has risen every year since the 2013 spinoff from Abbott, from $0.40 per quarter in 2013 to $1.73 today. The latest raise was 5.5%. The balance sheet is the weak spot. Book value stands at -3.359 per share, and management has committed to “achieving a net leverage ratio of two times within two to three years following the deal close” for the Apogee Therapeutics acquisition.

Bull case: Skyrizi sales rose 24.4% to $5.505 billion in the second quarter, and Rinvoq rose 24.5% to $2.525 billion. That carried total revenue up 10.16% to $16.99 billion. Shares are up 28.83% year to date at $285.82, yet the forward P/E is about 16.

Risk: Humira sales fell 35.9% to $756 million, and Imbruvica fell 29.4%. The stock also trades above the average analyst target of $283.50.

Amgen: Low Payout Ratio and Free Cash Flow That Nearly Doubled

Amgen (NASDAQ:AMGN) pays $2.52 per quarter, a 6% increase from a year ago. At a $10.08 annualized rate and a $447.28 share price, the yield is about 2.25%.

Dividend safety: The annual dividend uses roughly 45% of the low end of 2026 non-GAAP EPS guidance of $22.30 to $23.50, the smallest payout on this list. Second-quarter free cash flow rose 82.57% to $3.489 billion, after full-year 2025 free cash flow of $8.1 billion. Increases have come every year, from $0.28 a quarter in 2011 to $2.52 today.

Bull case: Six growth drivers, led by Repatha and TEZSPIRE, grew 26% and now generate nearly 70% of second-quarter product sales. Adjusted EPS of $6.29 beat the $5.6176 consensus, the fifth consecutive beat. The MariTide obesity program has ten Phase 3 studies ongoing or recruiting. The stock is up 39.44% year-to-date.

Risk: Debt stands at $57.3 billion, and leverage was 3.2x EBITDA at year-end 2025. Biosimilars cut Prolia sales 32% and XGEVA sales 34%, and TAVNEOS faces an FDA request for voluntary market withdrawal.

IBM: A Dividend Paid Every Year Since 1916 at a Discounted Price

IBM (NYSE:IBM) declared its $1.69 quarterly dividend on October 21, 2026, with an ex-dividend date of November 10 and payment on December 10. At $249.75, the $6.76 annualized rate works out to about a 2.71% yield.

Dividend safety: IBM returned $4.8 billion in dividends through the first nine months of 2026 while generating about $8 billion of free cash flow, a coverage ratio of about 60%. Third-quarter free cash flow rose 22.2% to $3.027 billion, and management now expects full-year free cash flow to increase by more than $1 billion. IBM has paid consecutive quarterly dividends every year since 1916, and the 2026 raise marked its 31st consecutive year of dividend increases. Those raises are small: the quarterly payout went from $1.68 to $1.69.

Bull case: Software revenue grew 8.2% to $7.804 billion, with Red Hat up 11% and Data up 19%. Annual recurring revenue grew 8% to $24.9 billion. The shares are down 13.96% year to date, which explains why IBM’s yield now tops every other name on this list except Chevron.

Risk: Debt totals $63.8 billion, including $12.7 billion linked to the financing business, after $11.4 billion in acquisitions year to date. IBM Z revenue fell 20%, and investors are still stomaching the July earnings miss.

Chevron: Record Production and 39 Straight Annual Raises

Chevron (NYSE:CVX) yields 2.87% on a $1.78 quarterly dividend, or $7.12 annualized. That is the highest yield in this group.

Dividend safety: The latest 4% raise marked Chevron’s 39th consecutive annual increase. The dividend equals about 69% of trailing EPS of $10.39, the highest payout ratio here. Cash flow carries it: second-quarter operating cash flow reached $22.633 billion and free cash flow hit $18.095 billion. That funded an $8.41 billion debt reduction and $3,117 million in buybacks in the same quarter.

Bull case: U.S. upstream output set a record at 2,077 thousand barrels of oil equivalent per day, and worldwide production rose 20%. Chevron reached $1.5 billion in annual run-rate Hess synergies within a year of closing, and its 20-year power deal with Microsoft for a 2.67 GW West Texas data center adds a cash stream that doesn’t depend on oil prices. The forward P/E is about 15.

Risk: Second-quarter results benefited from Brent at $104/BBL versus $68/BBL a year earlier, and first-quarter free cash flow was -$1.549 billion. After a 53.6% year-to-date gain, the $227.77 stock sits just below the $230.67 analyst target.

ExxonMobil: 43 Years of Dividend Growth Backed by Advantaged Barrels

ExxonMobil (NYSE:XOM) yields 2.35% on a $1.03 quarterly dividend, or $4.12 annualized.

Dividend safety: ExxonMobil has grown its annual dividend per share for 43 consecutive years, the longest streak in this group. The payout equals about 53% of trailing EPS of $7.77. Full-year 2025 free cash flow of $26.131 billion funded the dividend plus $20.0 billion in buybacks.

Bull case: First-quarter GAAP net income of $4.18 billion included $3.88 billion of derivative timing effects and $706 million in Middle East disruption losses. Underlying earnings rose to $8.77 billion from $7.58 billion. Guyana production topped 900,000 gross barrels of oil per day, and competitive Permian, Guyana, and LNG assets made up 59% of 2025 production. Cumulative structural cost savings since 2019 reached $15.60 billion.

Risk: First-quarter free cash flow fell 61.74% to $2.699 billion, and cash dropped 50.49%. After a 51.05% year-to-date run, the $178.23 stock trades near the $179.41 analyst target, and 15 hold ratings outnumber the 3 strong buy and 7 buy ratings.

Five Payouts Built to Outlast the Next Cycle

AbbVie and Amgen pay out roughly half of forecast earnings or less, while their fastest-growing drugs replace franchises lost to biosimilars. IBM offers the biggest valuation discount and a 110-year payment record backed by growing software cash flow. At the same time, Chevron and ExxonMobil add 39 and 43 years of raises funded by record production and cost cuts. Together they span pharma, enterprise tech, and energy. Each delivers cash flows with a dividend that is well covered heading into year-end.

Contact [email protected] for any questions or corrections.